Unusual Response of HDL-Chol Level and Body Weight to Atorvastatin: A Case Report

Area of Science:

• Cardiology
• Pharmacology

Background:

• Atorvastatin, an HMG-CoA reductase inhibitor, is commonly prescribed to manage hyperlipidemia and prevent cardiovascular events.
• Statins effectively lower low-density lipoprotein cholesterol (LDL-C) and triglycerides (TAG).

Observation:

• A patient experiencing an acute myocardial infarction was treated with atorvastatin.
• An unusual and significant dose-dependent reduction in high-density lipoprotein cholesterol (HDL-C) was observed during atorvastatin therapy.
• The patient also experienced unintentional weight loss, potentially linked to atorvastatin.

Findings:

• Atorvastatin effectively reduced LDL-C and TAG levels as intended.
• A notable and dose-dependent decrease in HDL-C was observed, a rare side effect of statin therapy.
• A correlation between atorvastatin use and unexplained weight loss was suggested.

Implications:

• This case underscores the importance of monitoring lipid profiles, including HDL-C, during atorvastatin treatment.
• Clinicians should be aware of the potential for significant HDL-C suppression and unexplained weight loss as rare adverse effects.
• Further research may be warranted to elucidate the mechanisms behind atorvastatin-induced HDL-C reduction and weight loss.